The global nutraceutical CDMO market size is projected to expand with a CAGR of 5.6% during the assessment period. The market value is expected to increase from USD 35,730.8 million in 2024 to USD 61,655.3 million by 2034.
In 2023, the nutraceutical CDMO industry was valued at USD 33,466.0 million and is anticipated to exhibit a y-o-y growth of 6.8% in 2024. This robust growth is indicative of the escalating demand for nutraceutical products across the globe.
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | USD 33,466.0 million |
| Estimated Market Size (2024) | USD 35,730.8 million |
| Projected Nutraceutical CDMO Market Value (2034) | USD 61,655.3 million |
| Value CAGR (2024 to 2034) | 5.6% |
In recent years, there has been a dramatic rise in the consumption of nutraceutical products due to increased health awareness and high interest in preventive healthcare. This, in turn, has put the nutraceutical CDMO industry into the limelight.
CDMOs provide end-to-end solutions encompassing research, development, manufacturing, testing, packaging, and logistics. This integrated approach streamlines the product development process, ensuring efficiency and reducing time-to-market.
The expertise of CDMOs is instrumental in formulating new and innovative nutraceutical products that meet evolving consumer demands. The focus on research and development within purpose-filled facilities allows CDMOs to stay at the forefront of industry advancements.
CDMOs are recognized for their ability to operate with agility and meet demanding timelines. Their streamlined processes and dedication to efficiency enable nutraceutical companies to bring products to market quickly, capturing opportunities in a rapidly evolving industry.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
The global market for nutraceutical CDMOs recorded a CAGR of 4.6% from 2019 to 2023. Total market valuation reached around USD 33,466.0 million at the end of 2023. Over the assessment period, the target market is projected to exhibit a CAGR of 5.6%.
| Historical CAGR (2019 to 2023) | 4.6% |
|---|---|
| Forecast CAGR (2024 to 2034) | 5.6% |
The global nutraceutical market is witnessing steady growth, fueled by increasing health awareness and a growing preference for preventive healthcare. Consumers today are more proactive in managing their well-being, seeking dietary supplements and functional foods to address specific health concerns. This shift in consumer behavior is a key driver shaping the trajectory of the global nutraceutical CDMO industry.
Nutraceutical CDMOs have emerged as critical facilitators in this vibrant market, responding to consumer expectations by offering a spectrum of innovative and high-quality products. These organizations leverage their technical expertise and purpose-filled facilities to develop formulations that resonate with the health-conscious consumer demographic.
One notable aspect of the consumer-driven demand is the growing interest in personalized nutrition. Consumers are increasingly seeking tailored solutions that cater to their unique health needs. Nutraceutical CDMOs are responding to this trend by providing customization options, allowing companies to create products that align with specific consumer preferences.
The nutraceutical industry is subject to increased regulations, and compliance is paramount. Nutraceutical CDMOs, equipped with manufacturing expertise and a deep understanding of regulatory requirements, are becoming increasingly attractive partners for brands looking to outsource production. The trend toward outsourcing is expected to rise as companies seek to navigate complex regulatory landscapes efficiently.
A rising focus on reducing overall nutraceutical product development costs is expected to boost sales in the market. Subsequently, the growing demand for dietary supplement CDMO services will foster growth.
According to the Journal of Clinical Sleep Medicine, with about 30% of United States adults experiencing insomnia, there is a pronounced demand for effective sleep support solutions. Nutraceutical CDMOs can leverage their formulation expertise and manufacturing capabilities to develop innovative sleep aid products. This includes the production of sleep-inducing supplements, herbal formulations, and other solutions designed to improve sleep quality.
The growing rates of anxiety, depression, and heightened awareness of stress management present an opportunity for CDMOs to contribute to the development of mood and mental health support products. By incorporating scientifically-backed ingredients, CDMOs can formulate supplements that address specific mood-related concerns, providing consumers with effective and safe options for mental well-being.
Nutraceutical CDMOs have the flexibility to tailor formulations to specific health needs within the sleep, mood, and brain health segments. This customization can include the incorporation of herbal extracts, vitamins, minerals, and other bioactive compounds known for their therapeutic effects. The ability to create tailored solutions enhances the market appeal of these products.
The opportunity for nutraceutical CDMOs lies in addressing the burgeoning demand for sleep, mood, and brain health solutions. To benefit from this, CDMOs are focusing on providing tailored formulations, investing in research and development, and collaborating with brands at the forefront of these segments.
CDMOs are becoming key enablers in providing effective, high-quality nutraceuticals that cater to the unique health needs of consumers. As the sales of nutraceutical products continue to rise globally, so will the demand for nutraceutical contract development and manufacturing services.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
One significant restriction affecting the nutraceutical CDMO market is the increasingly stringent regulatory landscape governing the production and marketing of nutraceutical products. Regulatory requirements, both at national and international levels, have become more complex, impacting the operations of CDMOs and influencing the overall market dynamics.
According to a report by the Global Organization for EPA and DHA Omega-3s (GOED), the regulatory environment for nutraceuticals has seen notable changes. For instance, in the United States, the Food and Drug Administration (FDA) has been focusing on implementing the Dietary Supplement Health and Education Act (DSHEA), ensuring the safety and quality of dietary supplements.
The European Food Safety Authority (EFSA) has been actively involved in evaluating health claims related to nutraceutical products, adding an additional layer of scrutiny. The need for compliance with stringent regulatory standards translates into increased compliance costs for nutraceutical CDMOs.
Investments in quality control, documentation, and adherence to Good Manufacturing Practices (GMP) become essential, impacting the overall operational expenses. The regulatory approval process for new formulations or ingredients can be time-consuming. Delays in obtaining approvals may hinder the speed-to-market advantage that CDMOs could otherwise offer to their clients, affecting the overall efficiency of product development.
The section highlights growth projections across prominent countries. China and Japan are predicted to register higher CAGRs of 7.4% and 3.4%, respectively, through 2034. This is due to the growing popularity of nutraceutical products in these nations. Similarly, the nutraceutical CDMO market in India and their emerging nations is expected to progress rapidly.
Market Growth Outlook by Key Countries
| Country | Value CAGR |
|---|---|
| United States | 1.8% |
| China | 7.4% |
| Japan | 3.4% |
| Germany | 1.7% |
| Spain | 2.8% |
The United States currently dominates the global nutraceutical CDMO industry with a share of around 32.6%. Over the forecast period, the United States nutraceutical CDMO market is expected to exhibit a CAGR of 1.8%.
The United has one of the leading markets for nutraceuticals globally. Rising health awareness and a growing aging population are creating a high demand for dietary supplements and functional foods in the United States. This, in turn, will boost the target market.
The presence of cutting-edge research facilities and a robust ecosystem for product development drives the demand for specialized services offered by nutraceutical CDMOs. The regulatory framework, including the Dietary Supplement Health and Education Act (DSHEA), provides a structured environment for the nutraceutical industry. This clarity contributes to the growth of the nutraceutical CDMO market by fostering compliance and ensuring product quality.
In 2023, China held a significant value share of 7.9% in the global nutraceutical CDMO market. Over the assessment period, demand for CDMO services in China is poised to grow with a CAGR of 7.4%.
China's rising middle class and increasing health and wellness awareness have fueled a growing demand for nutraceutical products. Similarly, the population's interest in preventive healthcare and dietary supplements has led to a thriving nutraceutical market. This is expected to drive the need for CDMOs to support the development and manufacturing of nutraceutical products.
The country’s government has shown support for the nutraceutical industry through favorable policies and regulations. The emphasis on health and wellness aligns with the government's broader public health initiatives, contributing to the growth of the nutraceutical CDMO market.
China is a key player in global manufacturing, and its nutraceutical CDMOs benefit from advanced manufacturing capabilities. The availability of cost-effective manufacturing services attracts both domestic and international companies looking for efficient production solutions.
Germany accounted for an 8.5% value share of the global market in 2023 and is expected to grow with a CAGR of 1.7% during the forecast period. This is due to the increasing consumption of functional foods and rising emphasis on research and innovation.
Germany is known for its commitment to quality and high manufacturing standards. Nutraceutical CDMOs in Germany often adhere to stringent quality control measures, attracting clients who prioritize product quality and safety.
The Germany market is characterized by sophisticated consumers who value premium and scientifically-backed nutraceutical products. CDMOs offering advanced formulation and production capabilities align well with the demands of this discerning market.
Germany has a strong emphasis on research and innovation in the healthcare sector. Nutraceutical CDMOs benefit from access to cutting-edge research and technology, contributing to their ability to offer innovative solutions to clients.
The section below highlights key segments' estimated market shares and CAGRs, including dosage form, services, and company size. This information can be vital for companies to frame their strategies accordingly.
Market Growth Outlook by Dosage Form
| Dosage Form | Value CAGR |
|---|---|
| Tablets & Capsules | 3.5% |
| Powder | 5.3% |
| Softgel | 6.9% |
| Liquid Formulations | 7.3% |
| Others (Gummies, Sprays, Sachets, Topical Forms) | 8.7% |
The tablets and capsules segment held a prominent market revenue share of 42.1% in 2023. Over the forecast period, the target segment is projected to advance with a CAGR of 3.5%. This is attributed to the rising popularity and consumption of nutraceutical tablets and capsules.
Tablets and capsules are popular dosage forms among consumers due to their convenience, ease of use, and familiarity. Many consumers find these solid oral dosage forms more convenient to incorporate into their daily routines than other formats like powders or liquid supplements.
Tablets and capsules are well-suited for high-volume manufacturing, making them cost-effective for both manufacturers and consumers. Hence, the target segment is expected to generate significant revenue in the global nutraceutical CDMO industry through 2034.
Market Growth Outlook by Services
| Services | Value CAGR |
|---|---|
| Product Formulation and Development | 5.3% |
| Manufacturing and Packaging | 4.7% |
| Research and Development | 6.1% |
| Analytical and Testing Services | 6.9% |
| Regulatory Support | 7.3% |
As per the latest analysis, demand remains high for nutraceutical manufacturing and packaging services in the market. The target segment held a market share of 33.1% in 2023. In the assessment period, it will likely grow with a CAGR of 4.7%.
Outsourcing manufacturing and packaging functions can be cost-effective for nutraceutical companies. CDMOs often have economies of scale, advanced equipment, and expertise in optimizing production processes, leading to cost savings for clients.
CDMOs specializing in manufacturing services often have extensive expertise in formulation development. This expertise allows them to create custom formulations that meet the specific requirements and preferences of nutraceutical brands, contributing to product differentiation and market competitiveness.
Market Growth Outlook by Key Company Size
| Company Size | Value CAGR |
|---|---|
| Small Companies | 5.8% |
| Mid-sized Companies | 4.7% |
| Large Companies | 7.3% |
The mid-sized companies segment accounted for a dominant industry share of nutraceutical CDMOs in 2023. Over the forecast period, it is poised to exhibit a CAGR of 4.7%.
Mid-sized CDMOs have the capability to offer personalized and customized services to their clients. Unlike larger CDMOs, they can provide a more hands-on and collaborative approach, working closely with clients to develop formulations, optimize processes, and meet specific requirements.
Mid-sized CDMOs are often characterized by a level of flexibility and agility that allows them to adapt quickly to changing market demands. As a result, the mid-sized companies category is expected to retain its market dominance through 2034.
Collaborations and acquisitions are common strategies employed by companies in the nutraceutical CDMO market to enhance their capabilities, expand their service offerings, and stay competitive in the dynamic landscape of advanced therapeutics. They are also integrating advanced technologies to improve their productivity.
Recent Developments in the Nutraceutical CDMO Market
| Attribute | Details |
|---|---|
| Estimated Market Size (2024) | USD 35,730.8 million |
| Projected Market Value (2034) | USD 61,655.3 million |
| Expected Growth Rate (2024 to 2034) | 5.6% CAGR |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; East Asia; South Asia & Pacific; Western Europe; Eastern Europe; Middle East & Africa |
| Key Countries Covered | United States, Canada, Mexico, Brazil, Chile, China, Japan, South Korea, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, BENELUX, Poland, Hungary, Romania, India, ASEAN Countries, Australia & New Zealand, Saudi Arabia, South Africa, Türkiye, Other African Union |
| Key Market Segments Covered | Dosage Form, Services, Company Size, and Region |
| Key Companies Profiled | Catalent; Lonza; Aenova Group; Akums Drugs and Pharmaceutical Ltd.; BASF SE; Sirio Pharma; Pharmavite LLC; Nature's Products, Inc.; PLT Health Solutions; Glanbia Nutritionals; Recipharm AB; B&D Nutritional Ingredients; NutraScience Labs; Vitakem Nutraceutical Inc.; Softigel (A division of Procaps Group); Iprona AG; Nutrilo GmbH; Atlantic Essential Products, Inc.; ProTec Nutra Ltd.; Nutraceuticals International Group |
| Report Coverage | Market Forecast, Competition Intelligence, Drivers, Restraints, Trends, Opportunities, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global market value is estimated to total USD 35,730.8 million in 2024.
The global nutraceutical CDMO market size is projected to reach USD 61,655.3 million in 2034.
Demand for nutraceutical development and manufacturing services is set to rise at 5.6% CAGR.
The manufacturing and packaging segment held a dominant market share of 33.1% in 2023.
The global market increased at a 4.6% CAGR from 2019 to 2023.
The United States accounted for a 32.6% share of the global market in 2023.
China is poised to register a CAGR of 7.4% between 2024 and 2034.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value Added Insights 5. Market Background 6. Global Market Demand (in Value or Size in USD million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Dosage Form 7.1. Tablets & Capsules 7.2. Powder 7.3. Softgel 7.4. Liquid Formulations 7.5. Others (Gummies, Sprays, Sachets, Topical Forms) 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Services 8.1. Product Formulation and Development 8.2. Manufacturing and Packaging 8.3. Research and Development 8.4. Analytical and Testing Services 8.5. Regulatory Support 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Company Size 9.1. Small Companies 9.2. Mid-sized Companies 9.3. Large Companies 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 10.1. North America 10.2. Latin America 10.3. East Asia 10.4. South Asia & Pacific 10.5. Western Europe 10.6. Eastern Europe 10.7. Middle East & Africa 11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14. South Asia & Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17. Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034 18. Market Structure Analysis 19. Competition Analysis 19.1. Catalent, Inc. 19.2. Lonza 19.3. Aenova Group 19.4. Akums Drugs and Pharmaceutical Ltd. 19.5. BASF SE 19.6. Sirio Pharma 19.7. Pharmavite LLC 19.8. Nature's Products, Inc. 19.9. PLT Health Solutions 19.10. Glanbia Nutritionals 19.11. Recipharm AB 19.12. B&D Nutritional Ingredients 19.13. NutraScience Labs 19.14. Vitakem Nutraceutical Inc. 19.15. Softigel (A division of Procaps Group) 19.16. Iprona AG 19.17. Nutrilo GmbH 19.18. Atlantic Essential Products, Inc. 19.19. ProTec Nutra Ltd. 19.20. Nutraceuticals International Group 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Nutraceutical CDMO Market
